Pancreatic cancer study links chemotherapy resistance to changes in surrounding cells

Chemotherapy changed cells surrounding pancreatic tumors, and a previously unrecognized subgroup was more abundant in patients who did not respond to treatment. Researchers at Tianjin Medical University Cancer Institute & Hospital traced how these cells promoted resistance to the drugs. Their study, published in Sci Transl Med, analyzed gene activity in individual cells from patient tumors. In mice, genetically removing the subgroup strengthened chemotherapy's effect against tumors.
The study examined pancreatic ductal adenocarcinoma, a highly lethal form of pancreatic cancer. Patients received albumin-bound paclitaxel combined with gemcitabine before surgery. The authors described this combination as a standard first-line approach for disease that is borderline operable or locally advanced. Resistance that develops during treatment is common, but the mechanisms behind it remain poorly understood.
The researchers focused on cancer-associated fibroblasts, cells in the tissue surrounding a tumor. Analysis of gene activity in individual cells showed that treatment shifted these fibroblasts from a muscle-like state toward an inflammatory state. It also identified a previously unrecognized subgroup producing TMEM100, a protein involved in the resistance mechanism. This subgroup was more abundant in tumors from patients who did not respond to treatment.
Experiments tracing the mechanism found that albumin-bound paclitaxel drove production of TMEM100. The fibroblasts producing TMEM100 released amphiregulin, a protein that sends signals to nearby cells. This activated signals within tumor cells that promoted resistance to chemotherapy.
In mouse models, genetically removing the fibroblasts producing TMEM100 reversed the shift in fibroblast states and increased the drug combination's effect against tumors. The authors identified this subgroup of surrounding cells as a promising target for making pancreatic ductal adenocarcinoma more sensitive to chemotherapy given before surgery.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].